Literature DB >> 7483772

Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines.

G R Siber1, R Anderson, M Habafy, R K Gupta.   

Abstract

There is currently no animal model which reliably predicts the immunogenicity of Haemophilus influenzae type b (Hib) polysaccharide-protein conjugate vaccines in human infants. We evaluated various Hib vaccines in guinea pigs using techniques similar to the United States potency test for adsorbed diphtheria and tetanus toxoids with a view to developing a method for evaluating the potency of a combined adsorbed tetanus, diphtheria, pertussis and Hib conjugate vaccine. Groups of 6-8 guinea pigs received 1.5 single human doses of vaccine at 0 and at 6 or 8 weeks and were bled at 6 weeks and 2 weeks after the booster injection. Total antibodies to polyribosylribitolphosphate (PRP), the Hib capsular polysaccharide, were measured in individual animals and in serum pools by radioimmunoassay. The relative antibody responses of guinea pigs to Hib conjugate vaccines qualitatively resembled those of human infants. Unconjugated polysaccharide was not immunogenic; PRP-D produced a low antibody response, HbOC, PRP-T (Merieux) and Hib-T (MPMBL) produced a low response to the first dose and a strong anamnestic response to the booster (geometric mean anti PRP > 1 micrograms ml-1). PRP-OMP uniquely produced a strong response after the first dose which was further boosted by the second dose. Experimental Hib-T vaccine lots with low levels of conjugation were poorly immunogenic in guinea pigs. Combinations of DTP and Hib-T vaccines showed equivalent or greater immunogenicity than Hib-T alone. We propose that the guinea pig model may be useful to verify the immunogenicity of PRP conjugate vaccines and for pre-clinical evaluations of DTP-Hib combination vaccines containing PRP conjugates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7483772     DOI: 10.1016/0264-410x(94)00042-l

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Use of immuno assays during the development of a Hemophilus influenzae type b vaccine for technology transfer to emerging vaccine manufacturers.

Authors:  Ahd Hamidi; Hans Kreeftenberg
Journal:  Hum Vaccin Immunother       Date:  2014-11-13       Impact factor: 3.452

2.  A strategy for rational design of fully synthetic glycopeptide conjugate vaccines.

Authors:  P Chong; N Chan; A Kandil; B Tripet; O James; Y P Yang; S P Shi; M Klein
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

3.  MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine.

Authors:  D M Granoff; Y E McHugh; H V Raff; A S Mokatrin; G A Van Nest
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

4.  Chemical synthesis of Haemophilus influenzae glycopeptide conjugates.

Authors:  A A Kandil; N Chan; M Klein; P Chong
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

5.  Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer.

Authors:  Ahd Hamidi; Pauline Verdijk; Hans Kreeftenberg
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

6.  Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.

Authors:  Stefan Fernandez; Emily D Cisney; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2013-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.